Jie Huang

发表

Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development

Julia N. Soulakova, Juan I. Young, F. Telischi, 2019, Neuro-oncology.

Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.

D. Welling, S. Kulp, C. Chen, 2009, European journal of cancer.

Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

D. Welling, C. Chen, Sarah S. Burns, 2013, Cancer research.

Inhibition of phosphatidylcholine‐specific phospholipase C prevents bone marrow stromal cell senescence in vitro

Shang Li Zhang, J. Miao, Yinshi Ren, 2009, Journal of cellular biochemistry.

Therapeutics , Targets , and Chemical Biology Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells , Potently Inhibiting NF 2-De fi cient Meningioma Growth

D. Welling, C. Chen, Sarah S. Burns, 2013 .

Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.

A. Kinghorn, D. Welling, A. Moberly, 2016, Neuro-oncology.

Genomewide DNA Methylation Responses in Patients with β-Thalassemia Treated with Yisui Shengxue Granules (益髓生血颗粒)

Zhi-kui Wu, Jie Huang, Su-ping Fang, 2019, Chinese Journal of Integrative Medicine.

Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation

D. Welling, Sarah S. Burns, Rulong Z. Shen, 2018, Experimental Neurology.

The MAX-interacting transcription factor network.

P. Hurlin, Jie Huang, 2006, Seminars in cancer biology.

CircFBXW7 alleviates glioma progression through regulating miR‐23a‐3p/PTEN axis

Jie Huang, Peng Yang, Zhi-Gang Gao, 2020, Anatomical record.

AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.

D. Welling, S. Kulp, Sarah S. Burns, 2011, Neuro-oncology.

Inflammatory Disease and Lymphomagenesis Caused by Deletion of the Myc Antagonist Mnt in T Cells

A. Wynshaw-Boris, P. Hurlin, Jie Huang, 2006, Molecular and Cellular Biology.

Identification of Inflammatory Genes, Pathways, and Immune Cells in Necrotizing Enterocolitis of Preterm Infant by Bioinformatics Approaches

Jie Huang, Lili Zhang, Minglin Wu, 2021, BioMed research international.

Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas

A. Kinghorn, M. Hollingshead, Sarah S. Burns, 2019, Molecular Cancer Therapeutics.

Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK

Steven P. Angus, David C. Jones, M. Ferrer, 2021, PloS one.

Knockdown of UBE2I inhibits tumorigenesis and enhances chemosensitivity of cholangiocarcinoma via modulating p27kip1 nuclear export

Xiao-long Tan, Jie Huang, Jian Luo, 2023, Molecular carcinogenesis.

Jie Huang , Anthony the Myc Antagonist Mnt in T Cells Lymphomagenesis Caused by Deletion of Inflammatory Disease and

A. Wynshaw-Boris, P. Hurlin, Jie Huang, 2005 .

Cyclin D1 Expression in Benign and Differentiated Malignant Tumors of the Thyroid Gland: Diagnostic and Biologic Implications

Michelle D. Reid, S. Looney, Jie Huang, 2012, Applied immunohistochemistry & molecular morphology : AIMM.

AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.

D. Welling, S. Kulp, Sarah S. Burns, 2011, Neuro-oncology.